PD25-03 TREATMENT WITH UGN-102 IN PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: 24-MONTH DURATION OF RESPONSE DATA FROM THE PHASE 3 ENVISION TRIAL
Sandip M. Prasad, Nikola V. Mihaylov, Pencho Genov, Vasyl Terzi et autres